{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T06:27:40Z","timestamp":1787120860152,"version":"build-2736575974"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neoadjuvant drug therapy has become an important component of multidisciplinary cancer treatment, but newer targeted, immunotherapy-based, and multi-agent regimens are often associated with higher costs and uncertainty regarding long-term economic value. This systematic review evaluates the economic evidence for neoadjuvant drug regimens in cancer and summarizes key cost-effectiveness findings across tumor types and healthcare settings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We systematically searched PubMed, Embase, and the Cochrane Central Register of Controlled Trials (CENTRAL) from database inception to June 1, 2026. Eligible studies were full economic evaluations comparing neoadjuvant drug regimens or assessing the addition of a specific drug component to a baseline neoadjuvant regimen in patients with cancer. Studies comparing neoadjuvant drug regimens with non-drug-based or non-neoadjuvant strategies were excluded. Study selection and data extraction were performed independently by two reviewers. Reporting completeness was assessed using the CHEERS 2022 checklist, potential sources of bias were assessed using the ECOBIAS checklist, and findings were narratively synthesized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 2,572 records were identified, and 7 studies met the inclusion criteria. The included studies were published between 2015 and 2024 and involved breast cancer, muscle-invasive bladder cancer, and borderline resectable or locally advanced pancreatic cancer. Five studies focused on breast cancer, mainly HER2-positive disease. Most studies used model-based approaches and quality-adjusted life-years as the primary outcome. Pertuzumab-based neoadjuvant regimens for HER2-positive breast cancer and FOLFIRINOX for pancreatic cancer were generally reported to be cost-effective in their respective healthcare settings. In contrast, neoadjuvant pembrolizumab for muscle-invasive bladder cancer and AC-TH compared with TCH for breast cancer were not cost-effective under base-case assumptions. Key drivers included pathological complete response, recurrence or progression risk, drug costs, utility values, adverse event costs, time horizon, and assumptions linking short-term efficacy to long-term outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Current economic evidence remains limited and concentrated mainly in HER2-positive breast cancer. Cost-effectiveness conclusions depend strongly on drug prices, downstream treatment costs, and model-based extrapolation of early efficacy endpoints. Future studies should incorporate long-term follow-up and real-world evidence.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420261462564<\/jats:ext-link>\n                      , Identifier CRD420261462564.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1918274","type":"journal-article","created":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:46:39Z","timestamp":1787118399000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Economic evaluations of neoadjuvant drug regimens in cancer: a systematic review"],"prefix":"10.3389","volume":"14","author":[{"given":"Ying","family":"Nie","sequence":"first","affiliation":[{"name":"School of Pharmacy, Hebei Medical University","place":["Shijiazhuang, Hebei, China"]},{"name":"Pharmaceutical Management Research Center of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohui","family":"Wang","sequence":"additional","affiliation":[{"name":"School of Pharmacy, Hebei Medical University","place":["Shijiazhuang, Hebei, China"]},{"name":"Pharmaceutical Management Research Center of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuo","family":"Kang","sequence":"additional","affiliation":[{"name":"Pharmaceutical Management Research Center of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]},{"name":"Medical Insurance Office, The Second Hospital of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenhua","family":"Pan","sequence":"additional","affiliation":[{"name":"Pharmaceutical Management Research Center of Hebei Medical University","place":["Shijiazhuang, Hebei, China"]},{"name":"School of Basic Medical Sciences, Hebei Medical University","place":["Shijiazhuang, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1186\/s13045-024-01640-8","article-title":"Global burden of cancer and associated risk factors in 204 countries and territories, 1980-2021: a systematic analysis for the GBD 2021","volume":"17","author":"Wu","year":"2024","journal-title":"J Hematol Oncol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/s0140-6736(22)01438-6","article-title":"The global burden of cancer attributable to risk factors, 2010-19: a systematic analysis for the global burden of disease study 2019","volume":"400","year":"2022","journal-title":"Lancet"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"2838","DOI":"10.1158\/1078-0432.Ccr-19-3492","article-title":"Pathologic complete response after neoadjuvant chemotherapy and impact on breast cancer recurrence and survival: a comprehensive meta-analysis","volume":"26","author":"Spring","year":"2020","journal-title":"Clin Cancer Res"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1001\/jamaoncol.2024.0057","article-title":"Neoadjuvant chemoimmunotherapy for NSCLC: a systematic review and meta-analysis","volume":"10","author":"Sorin","year":"2024","journal-title":"JAMA Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2409932","article-title":"Overall survival with pembrolizumab in early-stage triple-negative breast cancer","volume":"391","author":"Schmid","year":"2024","journal-title":"N Engl J Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1038\/s41467-024-45591-7","article-title":"Neoadjuvant-adjuvant pertuzumab in HER2-positive early breast cancer: final analysis of the randomized phase III PEONY trial","volume":"15","author":"Huang","year":"2024","journal-title":"Nat Commun"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in Resectable stage III melanoma","volume":"391","author":"Blank","year":"2024","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41591-023-02660-6","article-title":"Association between pathologic response and survival after neoadjuvant therapy in lung cancer","volume":"30","author":"Deutsch","year":"2024","journal-title":"Nat Med"},{"key":"ref11","year":"2022"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1007\/s40273-023-01242-1","article-title":"Comprehensive review of methods to assess uncertainty in health economic evaluations","volume":"41","author":"Otten","year":"2023","journal-title":"PharmacoEconomics"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1093\/jncimonographs\/lgac011","article-title":"Research on the economics of Cancer-related health care: an overview of the review literature","volume":"2022","author":"Davidoff","year":"2022","journal-title":"JNCI Monogr"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1007\/s40273-024-01413-8","article-title":"Systematic review of economic evaluations of systemic treatments for advanced and metastatic gastric cancer","volume":"42","author":"Sharma","year":"2024","journal-title":"PharmacoEconomics"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2020","journal-title":"BMJ"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"e067975","DOI":"10.1136\/bmj-2021-067975","article-title":"Consolidated health economic evaluation reporting standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"376","author":"Husereau","year":"2022","journal-title":"BMJ"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1586\/14737167.2015.1103185","article-title":"Risk of bias in model-based economic evaluations: the ECOBIAS checklist","volume":"16","author":"Adarkwah","year":"2016","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1080\/14737167.2023.2295474","article-title":"Cost-effectiveness analysis of add-on pertuzumab to trastuzumab biosimilar and chemotherapy as neoadjuvant treatment for human epidermal growth receptor 2-positive early breast cancer patients in Singapore","volume":"24","author":"Lim","year":"2024","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3111\/13696998.2014.979938","article-title":"Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada","volume":"18","author":"Attard","year":"2015","journal-title":"J Med Econ"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"732.e9","DOI":"10.1016\/j.urolonc.2021.03.004","article-title":"Cost-effectiveness analysis of neoadjuvant immune checkpoint inhibition vs. cisplatin-based chemotherapy in muscle invasive bladder cancer","volume":"39","author":"Khaki","year":"2021","journal-title":"Urol Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"e1565","DOI":"10.1002\/cnr2.1565","article-title":"Cost-effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab-paclitaxel in borderline resectable\/locally advanced pancreatic cancer patients","volume":"5","author":"Ingram","year":"2022","journal-title":"Cancer Rep (Hoboken)"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12962-021-00264-w","article-title":"Cost-effectiveness of paclitaxel, doxorubicin, cyclophosphamide and trastuzumab versus docetaxel, cisplatin and trastuzumab in new adjuvant therapy of breast cancer in China","volume":"19","author":"Xu","year":"2021","journal-title":"Cost Eff Resour Alloc"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"8265","DOI":"10.7314\/apjcp.2015.16.18.8265","article-title":"Cost-utility of \u201cDoxorubicin and Cyclophosphamide\u201d versus \u201cGemcitabine and Paclitaxel\u201d for treatment of patients with breast cancer in Iran","volume":"16","author":"Hatam","year":"2015","journal-title":"Asian Pac J Cancer Prev"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s10549-020-05587-5","article-title":"Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes","volume":"181","author":"Hassett","year":"2020","journal-title":"Breast Cancer Res Treat"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1080\/14737167.2025.2525224","article-title":"Challenges with integrating early-stage cancer trial endpoints into economic models: review of health technology recommendations for adjuvant or neoadjuvant therapies in Canada","volume":"25","author":"Beca","year":"2025","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1017\/s0266462325000017","article-title":"Use of surrogate endpoints in health technology assessment: a review of selected NICE technology appraisals in oncology","volume":"41","author":"Wheaton","year":"2025","journal-title":"Int J Technol Assess Health Care"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.jval.2025.07.010","article-title":"An assessment of the maturity of Cancer survival data used in economic models for the National Institute for health and care excellence's single technology appraisals","volume":"28","author":"Kang","year":"2025","journal-title":"Value Health"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1177\/0272989x241275969","article-title":"General population mortality adjustment in survival extrapolation of Cancer trials: exploring plausibility and implications for cost-effectiveness analyses in HER2-positive breast Cancer in Sweden","volume":"44","author":"Kim","year":"2024","journal-title":"Med Decis Mak"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1368718","DOI":"10.3389\/fpubh.2024.1368718","article-title":"Impact of the National Drug Price Negotiation policy on the price, usage, and affordability of anticancer medicines in Shandong Province, China","volume":"12","author":"Sun","year":"2025","journal-title":"Front Public Health"}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1918274\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T05:46:40Z","timestamp":1787118400000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1918274\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":29,"alternative-id":["10.3389\/fpubh.2026.1918274"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1918274","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"article-number":"1918274"}}